U.S. markets close in 4 hours 44 minutes
  • S&P 500

    3,258.03
    -52.08 (-1.57%)
     
  • Dow 30

    26,308.71
    -350.40 (-1.31%)
     
  • Nasdaq

    10,914.53
    -271.06 (-2.42%)
     
  • Russell 2000

    1,533.82
    -27.76 (-1.78%)
     
  • Crude Oil

    35.53
    -0.64 (-1.77%)
     
  • Gold

    1,883.40
    +15.40 (+0.82%)
     
  • Silver

    23.65
    +0.28 (+1.22%)
     
  • EUR/USD

    1.1686
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    0.8540
    +0.0190 (+2.28%)
     
  • GBP/USD

    1.2944
    +0.0021 (+0.16%)
     
  • USD/JPY

    104.6410
    +0.0310 (+0.03%)
     
  • BTC-USD

    13,433.85
    +135.01 (+1.02%)
     
  • CMC Crypto 200

    262.47
    -1.16 (-0.44%)
     
  • FTSE 100

    5,552.08
    -29.67 (-0.53%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2019

SAN DIEGO, March 02, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2019.

For the three months ended December 31, 2019, GIAPREZA U.S. net sales were $7.3 million, up 74% from the three months ended December 31, 2018 and up 28% from the three months ended September 30, 2019. Vials of GIAPREZA shipped from distributors to hospitals (hospital demand) grew 74% for the three months ended December 31, 2019 as compared to the three months ended December 31, 2018 and 18% as compared to the three months ended September 30, 2019. GIAPREZA U.S. net sales were $23.1 million in 2019 compared to $10.1 million in 2018, an increase of 129%. La Jolla announced the commercial availability of GIAPREZA in the U.S. in March 2018.

La Jolla’s net loss for the three and twelve months ended December 31, 2019 was $25.2 million and $116.5 million, or $0.93 per share and $4.30 per share, respectively, compared to $45.4 million and $199.5 million, or $1.73 per share and $7.85 per share, respectively, for the same periods in 2018.

As of December 31, 2019, La Jolla had $87.8 million in cash, compared to $172.6 million as of December 31, 2018. Net cash used in operating activities for the three and twelve months ended December 31, 2019 was $17.1 million and $85.0 million, respectively, compared to $32.0 million and $152.4 million, respectively, for the same periods in 2018. La Jolla has no debt.

About GIAPREZA

In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body’s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system, which in turn regulates blood pressure. Prescribing information for GIAPREZA is available at www.giapreza.com. GIAPREZA is marketed by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary.

IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

There is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis.

Adverse Reactions

The most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events.

Drug Interactions

Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see Full Prescribing Information for the United States.

About LJPC-0118

LJPC-0118 (I.V. artesunate) is La Jolla’s investigational product for the treatment of severe malaria. The active pharmaceutical ingredient in LJPC-0118, artesunate, was compared to quinine in patients with severe falciparum malaria infection in two randomized, active-controlled, clinical studies. In both studies, in-hospital mortality in the artesunate group was statistically significantly lower than in-hospital mortality in the quinine group. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation and Orphan Drug designation for LJPC-0118 for the treatment of malaria in April 2019 and July 2019, respectively. La Jolla filed a New Drug Application (NDA) with the FDA for LJPC-0118 for the treatment of severe malaria in the second half of 2019. Severe malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito. Symptoms include: fever, chills, sweating, hypoglycemia and shock. In 2013, an estimated 2 million cases of severe malaria occurred worldwide. In 2018, an estimated 405,000 people died from malaria worldwide.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla’s investigational product for the treatment of severe malaria. For more information, please visit www.ljpc.com.

Forward-looking Statements

This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: GIAPREZA™ (angiotensin II) sales; regulatory actions relating to La Jolla’s products by the U.S. Food and Drug Administration (FDA), European Commission and/or other regulatory authorities; cash used in operating activities and our capital requirements; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.


LA JOLLA PHARMACEUTICAL COMPANY

Consolidated Balance Sheets
(in thousands, except par value and share amounts)

December 31,
2019

December 31,
2018

ASSETS

Current assets:

Cash

$

87,820

$

172,604

Accounts receivable, net

2,960

1,381

Inventory, net

2,211

2,020

Prepaid expenses and other current assets

4,467

5,111

Total current assets

97,458

181,116

Property and equipment, net

18,389

22,267

Right-of-use lease asset

15,491

Restricted cash

909

909

Total assets

$

132,247

$

204,292

LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY

Current liabilities:

Accounts payable

$

4,177

$

8,572

Accrued expenses

9,312

8,485

Accrued payroll and related expenses

8,332

7,509

Lease liability, current portion

2,766

Deferred rent, current portion

1,370

Total current liabilities

24,587

25,936

Lease liability, less current portion

26,481

Deferred rent, less current portion

13,609

Deferred royalty obligation, net

124,379

124,323

Other noncurrent liabilities

12,790

4,503

Total liabilities

188,237

168,371

Shareholders’ (deficit) equity:

Common Stock, $0.0001 par value; 100,000,000 shares authorized,
27,195,469 and 26,259,254 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively

3

3

Series C-12 Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized,
3,906 shares issued and outstanding at December 31, 2019 and December 31, 2018; and liquidation preference of $3,906 at December 31, 2019 and December 31, 2018

3,906

3,906

Series F Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized,
0 and 2,737 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively; and liquidation preference of $0 and $2,737 at December 31, 2019 and December 31, 2018, respectively

2,737

Additional paid-in capital

977,432

950,258

Accumulated deficit

(1,037,331

)

(920,983

)

Total shareholders’ (deficit) equity

(55,990

)

35,921

Total liabilities and shareholders’ (deficit) equity

$

132,247

$

204,292



LA JOLLA PHARMACEUTICAL COMPANY

Consolidated Statements of Operations
(in thousands, except per share amounts)

Three Months Ended
December 31,

Twelve Months Ended
December 31,

2019

2018

2019

2018

Revenue

Net product sales

$

7,250

$

4,184

$

23,054

$

10,056

Total revenue

7,250

4,184

23,054

10,056

Operating expenses

Cost of product sales

787

1,200

2,392

1,643

Research and development

20,860

27,567

85,329

117,302

Selling, general and administrative

10,709

18,843

45,134

85,162

Total operating expenses

32,356

47,610

132,855

204,107

Loss from operations

(25,106

)

(43,426

)

(109,801

)

(194,051

)

Other (expense) income

Interest expense

(2,376

)

(2,722

)

(10,774

)

(7,303

)

Interest income

310

730

2,128

1,885

Other income—related party

1,939

1,939

Total other expense, net

(127

)

(1,992

)

(6,707

)

(5,418

)

Net loss

$

(25,233

)

$

(45,418

)

$

(116,508

)

$

(199,469

)

Net loss per share, basic and diluted

$

(0.93

)

$

(1.73

)

$

(4.30

)

$

(7.85

)

Weighted-average common shares outstanding, basic and diluted

27,169

26,242

27,112

25,422


LA JOLLA PHARMACEUTICAL COMPANY

Consolidated Statements of Cash Flows
(in thousands)

Year Ended December 31,

2019

2018

Operating activities

Net loss

$

(116,508

)

$

(199,469

)

Adjustments to reconcile net loss to net cash used for operating activities:

Share-based compensation expense

23,733

35,151

Depreciation and amortization expense

4,552

4,405

Loss on disposal of equipment

24

236

Non-cash interest expense

8,775

6,797

Non-cash rent expense

1,307

Changes in operating assets and liabilities:

Accounts receivable, net

(1,579

)

(1,381

)

Inventory, net

(191

)

(2,020

)

Prepaid expenses and other current assets

644

(1,964

)

Accounts payable

(4,395

)

(2,912

)

Accrued expenses

395

5,451

Accrued payroll and related expenses

823

2,514

Lease liability

(2,530

)

Deferred rent

824

Net cash used for operating activities

(84,950

)

(152,368

)

Investing activities

Purchase of property and equipment

(698

)

(2,340

)

Net cash used for investing activities

(698

)

(2,340

)

Financing activities

Net proceeds from issuance of common stock under ESPP

833

391

Net proceeds from issuance of common stock under 2013 Equity Plan

31

1,908

Net proceeds from royalty financing

124,289

Net proceeds from the issuance of common stock

109,809

Net cash provided by financing activities

864

236,397

Net (decrease) increase in cash and restricted cash

(84,784

)

81,689

Cash and restricted cash at beginning of period

173,513

91,824

Cash and restricted cash at end of period

$

88,729

$

173,513

Supplemental disclosure of non-cash investing and financing activities

Conversion of Series F Convertible Preferred Stock into common stock

$

2,737

$

Cumulative-effect adjustment from adoption of ASU 2018-07

$

(160

)

$

Initial recognition of right-of-use lease asset

$

16,798

$

Interest paid

$

1,999

$

506

Reconciliation of cash and restricted cash to the consolidated balance sheets

Cash

$

87,820

$

172,604

Restricted cash

909

909

Total cash and restricted cash

$

88,729

$

173,513


Company Contacts

Sandra Vedrick
Senior Director, Investor Relations
La Jolla Pharmaceutical Company
Phone: (858) 207-4264 Ext: 1135
Email: svedrick@ljpc.com

and

Dennis Mulroy
Chief Financial Officer
La Jolla Pharmaceutical Company
Phone: (858) 207-4264 Ext: 1040
Email: dmulroy@ljpc.com